research
A Twelve-Veteran Trial Tested Psilocybin for PTSD
The first U.S. pilot in severe treatment-resistant military PTSD reported no serious adverse events and substantial short-term remission.
Summary
The first U.S. pilot in severe treatment-resistant military PTSD reported no serious adverse events and substantial short-term remission.
Ohio State researchers enrolled 12 veterans with severe, treatment-resistant PTSD in a psilocybin-assisted therapy pilot. The team reported no serious adverse events or increase in suicidality, and nine participants met remission criteria one month after treatment. With no control group and a very small sample, the study establishes feasibility and a signal for larger trials, not treatment efficacy for the broader veteran population.
Why it matters
The first U.S. pilot in severe treatment-resistant military PTSD reported no serious adverse events and substantial short-term remission.
Limits and context
- With no control group and a very small sample, the study establishes feasibility and a signal for larger trials, not treatment efficacy for the broader veteran population.
Key claims
The first U.S. pilot in severe treatment-resistant military PTSD reported no serious adverse events and substantial short-term remission.
Qualification: With no control group and a very small sample, the study establishes feasibility and a signal for larger trials, not treatment efficacy for the broader veteran population.
Evidence: source-2026-07-31-014
Sources
- Ohio State University via Newswise: Psilocybin-assisted therapy pilot for veterans with PTSDThe Ohio State University · official announcement
Corrections
No corrections have been recorded for this story.